title: Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
abstract: Fludarabine was utilized in the conditioning regimen of 30 adult patients undergoing an allogeneic hematopoietic stem cell transplant. In 18 patients it was combined with full-dose busulfan (FluBu) as a myeloablative regimen and in 12 cases with melphalan (FluMel) as a reduced intensity conditioning (RIC) regimen. Patients in the FluBu group were younger than in the FluMel group (P=0.03). Of 30 patients, 24 received peripheral blood stem cells (PBSC) whereas six patients in the FluBu group received bone marrow cells. The hematological toxicity of each regimen was evaluated by analyzing the kinetics of the neutropenia induced by preparative regimens and the time to recovery of the absolute neutrophils count (ANC) and platelets post transplantation. In PBSC transplants, the median day of severe neutropenia (<500 ANC/microl) occurred on day +6 after the FluBu regimen and on day +3 after FluMel (P=ns), whereas both groups had a duration of severe neutropenia of 9 days and a comparable time for ANC and platelet engraftment. Extra-hematological toxicities were also comparable in the two groups. These findings suggest that the hematological and extra-hematological toxicities induced by fludarabine/full-dose i.v. busulfan are similar to those induced by a standard RIC regimen such as fludarabine/melphalan.
authors.affiliation: Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL 60607-7171, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chunduri
authors.forename: L C
authors.initials: LC
authors.lastname: Dobogai
authors.forename: D
authors.initials: D
authors.lastname: Peace
authors.forename: Y
authors.initials: Y
authors.lastname: Saunthararajah
authors.forename: H Y
authors.initials: HY
authors.lastname: Chen
authors.forename: N
authors.initials: N
authors.lastname: Mahmud
authors.forename: J
authors.initials: J
authors.lastname: Quigley
authors.forename: R
authors.initials: R
authors.lastname: Hoffman
authors.forename: E
authors.initials: E
authors.lastname: Jessop
authors.forename: R
authors.initials: R
authors.lastname: Beri
authors.forename: D
authors.initials: D
authors.lastname: Rondelli
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage; D005260:Female; D006085:Graft Survival / Q000502:physiology; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000494:pharmacology*; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine; D008558:Melphalan